Patients treated with matched therapies selected through biomarker or genetic testing can live longer.¹ The Pancreatic Cancer Action Network supports guideline recommendations for all patients to undergo genetic testing for inherited mutations at diagnosis and for patients to undergo biomarker testing of their tumor tissue unless clinically contraindicated. PanCAN offers precision medicine information and resources, including our Know Your Tumor® precision medicine service, for you and your patients.

MORE TREATMENT OPTIONS

Through our Know Your Tumor service, PanCAN will cover the cost of your patient’s genetic and tumor tissue biomarker testing by Tempus, a CLIA-certified laboratory. Tempus will provide you with a report, including information on both somatic and germline mutations, tumor burden (TMB) and microsatellite instability (MSI). The report includes treatment options, providing valuable insight to support your treatment decisions.

Treatment options are personalized to your patient and may include:

- Targeted therapy, which avoids the toxicity of multi-agent chemotherapy
- Appropriate clinical trials, including molecularly targeted solid tumor trials
- Off-label treatments that may be particularly effective for your patient’s specific tumor mutations
- Standard of care treatments

More than 400 physicians from 49 states have received Know Your Tumor reports for their patients. About 26% of patients’ tumors have been found to have at least one actionable alteration.

REPORT PROCESS

A Tempus representative will reach out to you to discuss the service and provide a tissue collection kit. You will also receive specific instructions for obtaining and shipping tumor tissue directly to Tempus. Once Tempus receives your patient’s tumor tissue, please allow 14 days for the complete report of personalized treatment options to be emailed.

“‘When I refer patients to Know Your Tumor, I feel like we join an all-star team with great resources dedicated to helping our particular patient.”

— Dr. Andrew E. Hendifar, medical oncology lead for the gastrointestinal disease research group at Cedars-Sinai Medical Center

¹. www.pancan.org/publicstatements